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Vinpocetine, a derivate of vincamine, is widely used in the clinical pharmacotherapy
of cerebral circulatory diseases. Herewith we report on a novel effect of
vinpocetine: inhibition of retrograde axoplasmic transport of nerve growth factor
(NGF) in the peripheral nerve. Blockade of retrograde transport of NGF results in
transganglionic degenerative atrophy (TDA) in the segmentally related ipsilateral
superficial spinal dorsal horn, which is characterized by depletion of the marker
enzymes fluoride-resistant acid phosphatase (FRAP) and thiamine monophosphatase
(TMP). At the same time, pain-related neuropeptides such as substance P (SP) and
calcitonin gene-related peptide (CGRP), are depleted from lamina I–III from the
segmentally related, ipsilateral Rolando substance of the spinal cord. On the basis of
these experiments it is suggested that vinpocetine may result in a locally restricted
decrease of nociception, that might be useful in clinical treatment of intractable
pain. Pilot self-experiments support this assumption.
& 2006 Elsevier GmbH. All rights reserved.Introduction
Central terminals of primary nociceptive neu-
rons, terminating in lamina I and II of the dorsal
horn in the form of scallopped terminals, containElsevier GmbH. All rights rese
2 544 918, +36 62 545 665;
ote.u-szeged.hupain-related neuropeptides (substance P (SP) and
calcitonin gene-related peptide (CGRP)), and the
marker enzymes fluoride-resistant acid phospha-
tase (FRAP) and thiamine monophosphatase or TMP
(Knyihar, 1971; Knyihar-Csillik et al., 1986). Pain is
known to be the central representation of nocicep-
tion transmitted to and perceived by the cerebral
cortex (Wall, 1995; Knyihar and Csillik, 2006).
In a series of publications (Knyihar and Csillik,
1976; Csillik et al., 1977, 1985, 2003; Knyihar-Csillikrved.
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it has been shown that blockade of retrograde
axoplasmic transport in a sensory nerve results in
transganglionic degenerative atrophy (TDA) of
central terminals of the affected primary nocicep-
tive neurons. Accordingly, transcutaneous ionto-
phoresis of vincristine was successfully performed
in order to alleviate chronic, neuropathic pain
deriving from postherpetic neuralgia, toxic poly-
neuropathies and terminal oncological states (Csil-
lik et al., 1982; Knyihar-Csillik et al., 1982; Szucs
et al., 1984; Csillik and Knyihar-Csillik, 1986; Tajti
et al., 1989; Rossano et al., 1989). However, this
treatment has been discontinued for fear of
unforeseen hepatotoxic side effects, that might
arise from the usage of vincristine and vinblastine,
known to be microtubule inhibitors.
Therefore, our interests was directed toward
another vinca alkaloid, vinpocetine. In this paper,
light- and electron microscopic effects of perineu-
rally applied vinpocetine, upon the marker en-
zymes (FRAP and TMP), and pain-related
neuropeptides (SP and CGRP) will be described in
the ipsilateral, segmentally related upper dorsal
horn. The effect of vinpocetine on the retrograde
axoplasmic transport of nerve growth factor (NGF)
in a peripheral nerve will be reported on the basis
of radiochemical studies. On this basis it is
suggested that transcutaneous iontophoresis of
vinpocetine might be promising to the pain clin-
ician, aiming to alleviate chronic, neuropathic
pain.Material and methods
Investigations were performed on 32 young adult
male albino rats (Rattus norvegicus albus), Wistar
strain, 200–250 g body weight. Care of the animals
complied with the guidelines of the Hungarian
Ministry of Welfare; experiments were carried out
in accordance with the European Communities
Council Directive (November 24, 1986; 86/609/
EEC) and the Guidelines for Ethics in Animal
Experiments of the Szeged University, Albert
Szent-Gyo¨rgyi Medical School.
For histochemical and immunohistochemical in-
vestigations, animals were anesthesized with 4%
chloral hydrate i.p. and subjected to transcardial
perfusion with a formaldehyde solution containing
picric acid (Zamboni and De Martino, 1965) to
which glutaraldehyde was added. The spinal cord
was excised and the distribution of FRAP and TMP
was studied in 15 mm frozen cross-sections, accord-
ing to the technique described earlier (Knyihar-Csillik et al., 1982, 1986; Csillik et al., 1986). SP
and CGRP immunoreactivity was visualized by
means of the techniques described by Csillik
et al. (2003).
In experiments aiming to study the effect of
vinpocetine on retrograde transport, a slab of
Gelita tampon (Braun, Melsungen, Germany) mea-
suring 5 5 20mm, was soaked in 106, 107 or
108 M vinpocetine (Sigma, catalog number V 6383)
dissolved in physiological saline. The slab was
applied around the sciatic nerve in the form of a
loose cuff, in five animals in each group. Contral-
aterally, the sciatic nerve was surrounded by a
similar Gelita tampon cuff, soaked in physiological
saline. Seven days after the application of the
cuffs, the animals were killed with an overdose of
chloral hydrate, and subjected to transcardial
fixation as described above.
For electron microscopic studies, FRAP and TMP
were visualized in vibratome sections of the spinal
cord (50 mm) as described above; however, the last
step of the reaction, i.e. sulfide treatment, was
omitted. The samples were embedded in Durcupan
ACM and sectioned on a Reichert Ultrotome. Thin
sections, silver interference color, were stained
with lead citrate and studied with a Zeiss Opton 902
electron microscope (Oberkochen, Germany).
The effect of vinpocetine upon retrograde
axoplasmic transport of NGF was studied after
injection of 600 ng (50 mCi) 125I-labelled NGF-b
under the skin of the hind paw. NGF prepared from
the murine submaxillary gland was obtained from
Sigma (St. Louis, MO, USA); 125I labeling was
performed according to the technique described
by Rohrer and Barde (1981). Radioactivity of 0.5 cm
long portions of the sciatic nerve, the correspond-
ing dorsal root ganglia and dorsal roots was
determined in a Berthold 8F Gammascint appara-
tus. The left sciatic nerves of the rats, seven
animals in each group were surrounded by Gelita
tampon cuffs, soaked in 106, 107 or 108 M
vinpocetine, dissolved in physiological saline. The
contralateral sciatic nerve was surrounded by a
Gelita tampon cuff, soaked in physiological saline.
The intensity of the histochemical reaction was
measured by densitometry of the slides, performed
by digitalizing microscopic pictures obtained by
histochemistry (FRAP, TMPase) or immunocyto-
chemistry (SP or CGRP) with a SPOT RT Slider CCD
camera (1600 1200 pixels, 8 bits) attached to a
Nikon Eclipse E600 microscope using a  16 front
lens and a  10 eyepiece. The captured images
were analyzed by ImageProPlus v4.5 morphometric
software (Media Cybernetics, Silver Sring, MD,
USA). Areas of interest were rectangular areas
measuring 50 200 mm. Fifteen rectangular fields
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randomly in different sections in a blinded manner.
Gray values of the selected areas were obtained
using a ScionNIH image analysis software. The
images were captured directly from the micro-
scopic slides, using a 5 objective lens by means
of a black and white camera Cohu CCD and
displayed on a computer monitor. The software
automatically assigned the average gray value of
the screen pixels corresponding to the outlined
area; a value of 0 indicated a white pixel and 225
indicated a black pixel.Results
Perineurally applied vinpocetine (Fig. 1), at a
concentration of 106 M, caused disappearance of
FRAP and TMP from the ipsilateral, segmentally
related Rolando substance (lamina II) of the dorsal
horn, within 7 days after application. At the same
time, there was no alteration seen contralaterally
(Fig. 2). If applied at a concentration of 107 or
108 M, perineurally applied vinpocetine caused
only a slight reduction in the histochemical
enzyme reaction. At a concentration of 109 M,
perineurally applied vinpocetine did not cause any
alteration.
At the electron microscope level, thousands of
scallopped axon terminals, displaying FRAP and
TMP enzyme reactions at their surface membranes,
could be observed under normal conditions
(Fig. 3a), which resulted in an enzyme active line
in lamina II at the level of the light microscope.Figure 1. Structural formula of vinpocetine (a) andAfter vinpocetine treatment of the sciatic nerve,
depletion of FRAP and TMP was accompanied by the
formation of enzyme inactive labyrinthine struc-
tures (Fig. 3b).
The effect of vinpocetine upon SP and CGRP
immunoreaction was evident but less conspicuous.
These neuropeptides are known to be localized in
lamina I and II but to a lesser degree also in lamina
III of the dorsal horn. Perineural application of a
Gelita tampon cuff containing 106 M vinpocetine
induced a decrease in SP and CGRP immunoreactiv-
ity in the ipsilateral, segmentally related upper
dorsal horn (Fig. 4). The effects of 107, 108, and
109 M vinpocetine were equivocal.
Densitometric measurements of the histochem-
ical (TMP) and immunohistochemical (SP) reactions
revealed that TMP was decreased significantly in
the ipsilateral spinal dorsal horn at levels corre-
sponding to vinpocetine treatment of the sciatic
nerve (po0:01). Contralaterally, and at irrelevant
levels, no significant alterations could be seen. A
decrease in ipsilateral SP immunoreactivity at the
spinal cord level corresponding to vinpocetine
treatment of the sciatic nerve was considerable
(po0:1). The corresponding values were as follows:
FRAP at level Th8: Mean 43.3, SEM: 0.71; SD: 2.26
FRAP at level L5, ipsilateral (vinpocetine treated):
Mean 12.1, SEM: 0.71; SD: 1.45
FRAP at level L5, contralateral (saline treated):
Mean 43.6, SEM: 0.56; SD: 1.78
SP at level Th8: Mean 34.9; SEM: 0.77; SD: 2.42
SP at level L5, ipsilateral (vinpocetine treated):
Mean 12.6; SEM: 0.45; SD: 1.43the Vinca alcaloids vincristin and vinblastin (b).
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Figure 2. TMP activity of the Rolando substance at the spinal cord level L5 after unilateral perineural vinpocetine
treatment (apparent right). Note virtual absence of TMP reaction at the projection of the cuff treatment (arrow) as
contrasted with the intense and uninterrupted enzyme reaction outlining lamina II contralaterally.
Figure 3. Electron microscopic appearance of FRAP under normal conditions in a scallopped axon terminal (S) in the
Rolando substance (a) and formation of an axonal labyrinth (arrow) devoid of any marker enzyme activity, 17 days after
application of a 106 M containing Gelita tampon cuff around the sciatic nerve (b).
Figure 4. Substance P immunoreactivity of the upper dorsal horn at the spinal cord level L5 after unilateral perineural
vinpocetine treatment (106 M) of the sciatic nerve (apparent right). Note decreased substance P immunoreaction at
the site of projection of the cuff treatment (arrow), as contrasted to the intense immunoreaction outlining lamina and I
and II contralaterally (arrow with asterisk).
E. Knyihar-Csillik et al.42SP at level L5, contralateral (saline treated): Mean
36.6; SEM: 0.48; SD: 1.50
SEM: standard error; SD: standard deviation.
Radiochemical measurements of [125I] NGF in
0.5 cm long portions of the sciatic nerve revealed
that in control animals, where the sciatic nerve was
surrounded by a Gelita tampon cuff soaked in
isotonic saline, radioactivity of [125I] NGF was moreor less evenly distributed throughout the entire
length of the sciatic nerve. Concentration of
radioactivity was seen in the related dorsal root
ganglia (Fig. 5).
After perineural treatment of the sciatic nerve
with 106 M vinpocetine, retrograde transport of
125I-labeled NGF was virtually blocked at the site of
the cuff. A conspicuous accumulation of 125I was
observed just distal to the cuff and in the region of
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Figure 5. Distribution of radioactivity in the sciatic nerve, in dorsal root ganglion L5 and in the related dorsal root, 15 h
after injection of 600 ng (50mCi) of 125I-labelled NGF-b under the skin of the hind paw, 72 h after perineural application
of physiological saline in a Gelita tampon cuff. #1 is the most distal portion, #13 is the dorsal root ganglion and #14 is
the dorsal root. The isotonic saline cuff was applied at portions #7 and #8 (arrows).
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Figure 6. Distribution of radioactivity in the sciatic nerve, in dorsal root ganglion L5 and in the related dorsal root, 15 h
after injection of 600 ng (50mCi) of 125I-labelled NGF-b under the skin of the hind paw, 72 h after perineural application
of 106 M vinpocetine in a Gelita tampon cuff. #1 is the most distal portion; the vinpocetine cuff was applied at #7 and
#8 (arrows); #13 is the dorsal root ganglion and #14 is the dorsal root. Asterisks indicate significant alterations (increase
in #6; decrease in #13) as compared to control experiments.
Vinpocetine and axoplasmic transport 43the cuff itself. In portions proximal to the cuff, as
well as in dorsal root ganglia and dorsal roots,
radioactivity was significantly lower than in con-
trols (Fig. 6). After perineural treatment of the
sciatic nerve with 107 or 109 M vinpocetine
containing cuffs, the retrograde transport of 125I-
labeled NGF was virtually unchanged.Discussion
According to the enzyme histochemical, immu-
nocytochemical and neurochemical studies de-scribed above, perineurally applied vinpocetine
induces blockade of retrograde axoplasmic trans-
port which consequently results in TDA in the
ipsilateral, segmentally related upper dorsal horn.
Vinpocetine, a derivate of vincamine, is proven to
be devoid of any unwanted side effects. It is widely
used in clinical pharmacotherapy of various cere-
bral circulatory diseases such as memory problems,
motion disorders, climacterial complaints, vertigo
and headache (Bonoczk et al., 2000). Vinpocetine is
a drug very different from vincristine: principally,
its effect is blockade of sodium channels (Sitges
et al., 2005; Zhou et al., 2003) and of Ca2+ channels
ARTICLE IN PRESS
E. Knyihar-Csillik et al.44(Sitges and Nekrassov, 1999) as well as of glutamate
receptors (Kiss et al., 1991). The chemical struc-
ture of vinpocetine, a derivate of Vinca minor L.,
shows little resemblance, if any, to that of
vincristine and vinblastine, obtained from Vinca
major L.
The effects of vinpocetine upon retrograde
axoplasmic transport are very similar to those
exerted by vincristine and vinblastine, two semi-
synthetic derivates of Vinca major L. (Knyihar-
Csillik and Csillik, 1981). TDA caused by vinpocetine
is followed by the appearance of labyrinthine
structures similar to those found earlier in the
upper dorsal horn after perineural application of
microtubule inhibitors vincristine and vinblastine
(Knyihar and Csillik, 1976; Csillik et al., 1977).
FRAP has been suspected to be a genuine marker
enzyme of nociception as early as more than three
decades ago (Knyihar, 1971); yet this idea was
supported by experimental facts only considerably
later (Schoenen et al., 1985; Glykys et al., 2003).
TMP, an isoenzyme of FRAP (O’Brien et al., 1989)
undergoes alterations in the course of TDA similar
to those of FRAP. SP and CGRP are regarded as pain-
related neuropeptides (Snyder and McMahon,
1998). Disappearance of FRAP and TMP, and dimin-
ishment of SP and CGRP from the upper dorsal horn,
can thus be suspected to be signs of a decreased
nociception.
Vinpocetine was first synthesized by Lorincz
et al. (1976) from the alkaloid vincamine, obtained
from the leaves of Vinca minor L. (Bonoczk et al.,
2000). According to the studies of the Marburg
school of pharmacologists, vinpocetine prevents
ischemic cell damage in the hippocampus (Sauer
et al., 1988); it enhances cerebral blood flow and
glucose utilization after forebrain ischemia
(Rischke and Krieglstein, 1990). Vinpocetine was
reported to protect against excitotoxic cell death
of cerebrocortical neurons (Erdo et al., 1990); it
increases the neuroprotective effect of adenosine
in cell cultures (Krieglstein and Rischke, 1991).
According to Bonoczk et al. (2000) positron emis-
sion tomography proves that vinpocetine is able to
redistribute regional cerebral blood flow and
enhance glucose supply of brain tissue in ischemic
post-stroke patients. Lendvai et al. (2003) have
shown that vinpocetine enhances morphological
dynamics of dendritic spines of pyramidal cells in
the neocortex.
Our studies reported here prove that perineurally
applied vinpocetine is able to block retrograde
axoplasmic transport of NGF in a peripheral nerve
that induces TDA of primary sensory axon terminals
in the segmentally related, ipsilateral upper dorsal
horn, resulting in the depletion of FRAP and TMP,and partial depletion of SP and CGRP from the same
area. Similar effects were observed earlier after
perineural application of vinblastine and vincris-
tine; also the blockade of retrograde axoplasmic
transport of 125I NGF after perineural application of
vinpocetine is similar to that observed by us after
perineural application of vinblastine and vincristine
(Csillik et al., 1985). Since transcutaneous ionto-
phoresis of vincristin and vinblastin alleviates
chronic pain resulting from postherpetic, trigem-
inal and other neuralgias (Csillik et al., 1982), the
possibility arises that vinpocetine, applied by
transcutaneous iontophoresis, can also be used for
alleviation of pain. Since iontophoretic administra-
tion of vinpocetine is feasible (Musaev et al., 1998)
it can be assumed that iontophoretically applied
vinpocetine may be effective in alleviation of
chronic pain. Recent studies of Hua et al. (2004)
revealed that an optimized microemulsion of
vinpocetine represents a nonirritant transdermal
delivery system. Accordingly, transdermal or trans-
cutaneous administration of vinpocetine seems to
be a promising possibility in the clinical treatment
of neuropathic pain.Acknowledgements
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